My ePortfolio Register   

Selumetinib in children with recurrent or refractory low-grade glioma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.17
Views: 3788

Dr Jason Fangusaro - Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, USA

Dr Fangusaro speaks with ecancer at ASCO 2017 about the results of a phase II multicentre prospective study of the efficacy of the MEK I/II inhibitor selumetinib in children with recurrent and refractory low-grade glioma. There was a 30-40% response rate in patients for whom multiple previous therapies had failed.

He notes that selumetinib was fairly well tolerated by patients. The most common toxicities were Grade 1 and 2, and included nausea, diarrhoea, asymptomatic CPK elevation, rashes and paronychia.

Other arms of the trial have been expanded based on results in the early groups. Dr Fangusaro is hopeful selumetinib will soon be used as a first-line therapy.

The trial is conducted by the Paediatric Brain Tumour Consortium, an NCI funded group overseen by CTEP.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence